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SUMMARY:
Current knowledge on the pathophysiology of  sickle cell anemia is reviewed and potential thera-
peutic options are reviewed and discussed. It is hoped that better understanding of the pathophysiology will
improve the care given to these patients as well as their quality of life.
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RESUME :
Il s’agit d’une revue de la littérature sur les connaissances récentes de la physiopathologie de la
drépanocytose ainsi que les options potentielles du traitement.
Le souhait est que la meilleure connaissance de la physiopathologie, permette d’améliorer la prise en charge
et la qualité de vie de ces patients.
Mot clés : Drépanocytose –Physiopathologie - Traitement
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I - INTRODUCTION
Sickle cell anemia (SCA), is an inherited
condition resulting from an abnormality in the
β-chain of adult hemoglobin (HbA). The amino
acid valine replaces glutamic acid which is
normally present at the sixth position at the
amino terminal. On deoxygenation HbS
polymerizes and forms long crystals that distort
the erythrocyte membrane [1-2].















). The minor adult hemoglobin component
HbA
2
 is seen only when significant amounts of
HbA are present. At birth,  less than 1% of HbA
2
is seen, by 12 months 2-3.4% and throughout
life the normal ratio of HbA to HbA
2
 is about
30:1.  By 6-12 months of age, the normal adult
hemoglobin pattern appears, and HbF is present
only in traces. High levels of β-chain and thus
HbS are not produced until 3-6 months post
natal life so symptoms of the disease are rare
before 3 months [3].
Although little is known about the
mortality from inherited hemoglobin disorders
in developing countries, it is clear that in sub-
Saharan African, many children die from them
early in life. Both in the USA and Jamaica, the
peak incidence of death among those affected
with these disorders is at 1-3 years of age,
usually due to infection. Recent data from the
USA, suggests that among affected adults, the
median age of death is 42 years for males and
48 years for males[4].
In recent years, there has been
impressive progress in understanding the
molecular pathogenesis and development of
new therapeutic agents, for SCA.
1I - PATHOPHYSIOLOGY [1,2,5]
When sickle hemoglobin (hemoglobin
S) is deoxygenated, the replacement of β6
glutamic acid with valine results in a
hydrophobic interaction with another
hemoglobin molecule, triggering an aggregation
into large polymers. Sickle cell trait is benign,
because the cellular concentration of
hemoglobin S is too low for polymerzation to
occur and it is hemoglobin S polymers that
cause the cellular injury responsible for the
clinical manifestations.
When deoxygenated, cells containing
hemoglobin assume a banana or sickle shape
and transmission electron microscopy reveals
the presence of bundles of fibres oriented along
the long axis of the cell.
The kinetics of polymer formation are
critical determinants of the shape and morphology
of the cells. When deoxygenation is rapid,
multiple independent polymerization events result
in a granular texture that does not alter the cell’s
disk-like shape. Contrarily, when deoxygenation
is slow, a single nucleus of aggregated molecules
of deoxygenated HbS is formed. This nucleation
is followed by the growth and alignment of fibres,
transforming the cell into a classic sickle cell
shape. The distortion of the shape of the cell by
projections of aligned hemoglobin, has a critical
role in perturbing the structure and function of
the membrane in SS red cells. The rate and extent
of polymer formation in a circulating SS red cell,
depend on 3 independent variables :
- the cells’ degree of deoxygenation
- the intracellular hemoglobin concentration
- the presence or absence of HbF
Although the mean intracellular
hemoglobin concentration and mean density of
the overall population of SS red cells are close to
those of normal cells, the density distribution of
SS red cells is unusually broad. The increase in
the least dense SS cells is due primarily to a high
number of reticulocytes with a relatively low
intracellular hemoglobin concentration. The
presence of a substantial population of very dense
cells is the result of polymerisation-induced
membrane damage leading to enhanced
dehydration.  The end result of this process is the
irreversibly sickled cell, with an elongated shape,
even after fully oxygenated and lacks polymers.
Since the rate of polymerisation of deoxygenated
hemoglobin S is dependent on the hemoglobin
concentration, dense SS cells is much likely to
become distorted and rigid and thus contribute to
the vaso-occulsive and hemolytic aspects of the
disease.
The most important contributors to the
dehydration of SS red cells are potassium-chloride
cotransport and Ca++ - activated K+ efflux. In
normal AA red cells, the former transport
mechanism is active only in reticulocytes. Potas-
sium – chloride cotransport is induced by cell
swelling and acidification.
SS red cells have increased amounts of calcium,
compartmentalized within intracellular vesicles,
with normal steady-state concentrations of Ca++
in the cytosol. When the cell membrane is
distorted by sickling, there is a transient increase
in cytosolic Ca++.
The increase is sufficient to trigger the Ca++ -
dependant (Gardos) K+ channel, thus providing
a second pathway for sickling-induced loss of K+
and water and leading to cell dehydration.
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The Gardos channel is activated by both
increased intracellular calcium levels and
agonists such as prostaglandin E
2.
  Since the
potential for a sickled cell to initiate a vaso-
occlusive event depend mostly on whether the
rate of polymer formation is within the range
of the capillary transit time, anything that
retards transit of SS red cells in the
microcirculation can have a critical effect on
the pathogenesis of vaso-occulsion in SCA.
Studies under static and dynamic conditions
have demonstrated that SS red cells have a
sticky surface and attach more readily than
normal cells to monolayers of cultured
endothelial cells. Recent studies have
delineated the molecular interactions
responsible for the adhesion of SS red cells to
endothelium:
-  reticulocytes especially those from SS





, which binds to both fibronectin
and vascular-cell adhesion molecule 1. This
latter molecule is expressed on the surface of
endothelial cell, especially after activation by
inflammatory cytokines as tumour necrosis α,
interferon-γ IL-1β, vascular endothelial growth
factor (VEGF), thrombin, histamine and the
effects of hypoxia and reperfusion.
-  reticulocytes that are prematurely realeased
form, the bone marrow (“stress”reticulocytes)
in hemolytic disease display additional adhesive
ligands that facilitate interactions between
sickle cells and endothelial cells.
-  microvascular endothelial cells and a
subpopulation of sickle reticulocytes have
CD36, which binds to thrombospondin secreted
by activated platlets.
-  several other plasma proteins including very
– high – molecular weight forms of von
Willebrand factor, may make an important
contribution to adhesion.
-  granulocytes interact with sickle cells and
endothelial cells, and are stimulated to release
injurious cytokines.
From extensive in vitro studies, in recent years,
it has been concluded that sickle red cells indeed
exhibit an increased adhesive phenotype and
many cell adhesion receptors, plasma protons
and sub endothelial matrix components are
involved in mediating adhesive interactions. As
the phenomenon of cell adhesion is better
understood, it is likely that anti-adhesion
therapies may become viable therapeutic
alternatives in the management of vaso-
occulsive crisis in the next decades. Although
the major effects of SCA, result from the non-
delivery of oxygen by abnormal blood, it is also
likely that oxygen delivery may also be
impaired by increased blood viscosity without
 primary adhesion and occlusion as described
above. The viscosity of a fluid is defined as the
resistance to flow of that fluid and is determined
by some factors as temperature and the intrinsic
properties of the fluid.
Several studies done to define the intrinsic
characteristics that are altered in SCA, all indicate
that membrane viscosity and the internal viscosity
and deformability in SCA is markedly altered even
when the cell is fully oxygenated. These are
markedly increased when the hemoglobin is
deoxygenated. This is because the hemoglobin
molecules are no longer randomly arranged when
deoxygenated but form structured, elongated
arrays. The increase in viscosity is greater when
deoxygenation is sudden and  rapid than when it
is gradual. The increased erythrocytic intracellular
and membrane viscosity translates directly into
whole blood viscosity.
        Another important determinant of blood
viscosity is the hematocrit. For normal blood,
viscosity rises linearly as the hematocrit is
increased. At very high hematocrits, viscosity may
rise at a greater rate than the rate of rise of
hematocrit, and oxygen delivery can start to
decrease at hematocrits of 45-50% and the
decrease becomes dramatic at a hematocrit of
60%. This decrease reflects the diminished
circulation in small vessels as whole blood
viscosity rises. The effect of hematocrit is more
striking when HbS is examined. At full oxygen
saturation, the curve relating viscosity to
hematocrit is much steeper than for normal
hemoglobin and deoxygenation makes it steeper
still.
The curve relating oxygen delivery to
hematocrit is strikingly shifted (even with full
oxygenation) and indicates that the diminution of
oxygen delivery begins at hematocrits of 30-35%
and is striking at hematocrits of 45%. Diminished
oxygen delivery results in tissue hypoxia and
further desaturation of the hemoglobin.
The effects of increased viscosity on the
circulation are seen in the larger vessels than the
effects of adherence and occlusion. If the
consequent hypoxia is sufficiently prolonged in a
sufficiently large volume of tissue, necrosis
results. Another important effect of increased
whole blood viscosity is the increased tendency
to thrombosis, probably due to the slowed rate of
circulation. Thrombosis can be seen on either the
arterial or venous side of the circulation.
Since the main effect of an increased hematocrit
in SCA is a striking increase in blood viscosity,
its measure can serve as a surrogate for the effect
of increased viscosity in the pathogenesis of the
disease.
III - THERAPEUTIC APPROACHES
Treatment for SCA is rapidly evolving as
better understanding of the pathophysiology
improves.
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The following section reviews newer and
emerging treatments.
1) Chemical inhibition of hemoglobin S [2,6]
The substitution of valine for glutamic acid at
position 6, creates a hydrophobic pocket in the
hemoglobin tetramer that readily polymerises on
deoxygenation. The development of drugs that
specifically bind sickle hemoglobin and inhibit
polymerisation was based on biochemical
principles for disrupting the hydrophobic
interactions between the deoxyhemoglobin S
tetramers, and has been further refined using the
three dimensional structure of hemoglobin S and
site mutagenesis. The development of a safe and
effective inhibitor agent is a great challenge. The
ideal agent would be readily absorbed through
the gastrointestinal tract, circulate in the plasma
without binding strongly to plasma proteins,
readily penetrate the erythrocyte membrane and
bind strongly and specifically to hemoglobin S
to inhibit polymerisation. It should also not affect
physiologic oxygen transport or bind to other
biologically important molecules. A large amount
of drug would be necessary to bind to the
approximately 400 g of hemoglobin in patients
with SS disease.
Unfortunately no antisickling drug so far tested,
has a ratio of efficacy to toxicity that is high
enough to merit clinical use.
2) Reduction of the intracellular hemoglobin
concentration [2,6]
Since the rate of polymerisation of sickle
hemoglobin is dependent on Hb S concentration,
any treatment that lowers the mean corpuscular
hemoglobin concentration is rationale.
Clotrimazole (an antifungal drug) specifically
inhibits the Gardo’s channel, inhibiting K+ and
water loss from SS red cells and thus reducing
the intracellular hemoglobin concentration.
Magnesium supplementation also effectively
retards K+ and water loss from SS red cells in
vitro.  Two trials have shown the effectiveness
of zinc sulphate and piracetam in preventing
sickle cell related crisis in a total of 246 patients,
by preventing red blood cell dehydration [7]. A
reduction in  pain crisis was shown in the
piracetam study over a one year period and in
the zinc trial a significant reduction in the total
number of pain, hemolytic, aplastic and
sequestration  crisis was observed  over a period
of one and a half  years.  While these results are
encouraging, larger and / or longterm multicenter
studies are needed to further evaluate efficacy.
3) Role of vasoactive modulators in sickle cell
anemia [6]
The sickle erythrocyte has been shown
to produce adverse morphologic changes and
modulations of the vasoregulatory molecules in
exposed endothelial cells.
Nitric oxide is an important regulator of normal
vascular tone and also binds directly to
hemoglobin at both the heme iron and thiol
groups, and is delivered to the tissues as oxygen
is delivered. Experimental studies in the rat show
that nitric oxide maintains organ blood flow in
the presence of sickle red cells. In man, inhaled
nitric oxide increases oxygen affinity in sickle
red cells, and is well tolerated. Thus, nitric oxide
may be a useful therapy for the treatment of
vasoocculsion in SCA both as a vasomodulator
and as an antisickling agent.
4) Treatment of sickle cell painful episodes
[8]
Current treatment of acute painful
episodes of SCA is primarily supportive and
includes hydration, heat packs, oxygen,
antibiotics, analgesics and blood transfusions.
Painful episodes and the associated end organ
damage are caused by microvascular occlusion,
tissue ischemia resulting from complex
interactions between the sickle erythrocytes,
endothelium, platlets, plasma clotting factors
and certain inflammation mediators.
Poloxamer 188 (Rheoth RxÒ), a nonionic block
copolymer composed of blocks of hydrophobic
polyoxpropylene and hydrophilic
polyoxyethylene has hemorrheologic properties
and has been shown to improve microvascular
blood flow by lowering viscosity and adhesive
frictional forces. Rheoth RxÒ provides a
hydrated, poorly compressible barrier that blocks
hydrophobic adhesive interactions (cell-cell,
cell-protein, and protein-protein) in the blood.
As a result, there is a reduction in blood viscosity,
erythrocyte aggregation, adhesion to vascular
endothelium, and an improvement in
microvascular blood flow, thus reducing painful
episodes in SCA.
5) Induction of fetal hemoglobin synthesis
Nearly 56 years of clinical and basic
research have established that high hemoglobin
F concentrations reduce the severity of SCA by
preventing formation of hemoglobin S polymers
[1,5].
The first drug to be tested was 5 –
azacytidine, an antineoplastic drug, and was
shown to increase HbF concentration, in
phlebotomized baboons. But was abandoned
because HbF production was via cytoxicity
rather than gene hypomethylation [5].
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Analogues of butyrate as well as acetate
and other short-chain fatty-acid derivatives also
appear to induce HbF production [2,6].
Presently the use of these drugs remains
experimental [5].
Hydroxyurea is currently the only drug
in widespread use, known to stimulate HbF
production.  It is relatively non-toxic, its
myelosuppressive effects reversible and not
known to induce tumours [2]. It has no role in
the treatment of crisis in progress [9].
Hydroxyurea blocks DNA synthesis by
inhibiting ribonucleotide reductase from
ribonucleoside precursors [5,9]. It acts on bone
marrow by its cytotoxic effects, selects a po-
pulation of erythroblasts that can synthetize
increased amounts of HbF. There are no direct
effects on gene expression, and bone marrow
cellularity may be diminished. Higher concen-
trations of HbF, reduce the level of HbS
polymers and the numbers of deformed, dense
and damaged erythrocytes. Cells with a high
HbF content survive longer, attenuating
hemolysis and leading to a reduction in
reticulocytes, circulating granulocytes, mono-
cytes and platelets. Fewer dense, poorly
adhesive erythrocytes are less apt to adhere to
and perturb the endothelium reducing the
likelihood of vasoocculsion. Two other





CD34 also drop during hydroxyurea treatment
[5,6]. Recent reports suggest novel methods of
action which include generation of nitric oxide
(NO) by peroxidation, increased erythropoitin
and induction of methemoglobin formation [5].
Therapy should be started with 500mg
of hydroxyurea or 10 to 15mg/kg of body
weight,and after six to eight weeks of treatment,
the dose may be increased to 1000mg per day
if blood counts are stable  [1,10].  Hydroxyurea
should be given for a trial period of at least 60
days before a patient is determined not to be
responding to the drug [10]. Some authors used
higher doses in children (14 - 27mg/kg body
weight daily) and had good results and
tolerance [11]. In about 10 to 25% of adult
patients, hydroxyurea treatment does not cause
an increase in HbF, perhaps because of
abnormal bone marrow, genetic factors and
variations in drug metabolism [1]. Doses of
hydroxyurea that achieve fetal hemoglobin
responses are at or near threshold of marrow
suppresion [10].Studies of hydroxyurea in in-
fants, children and adolescents lag behind adult
studies in the appraisal of clinical efficacy.
 All trials show an increase of HbF from about
5% before treatment to about 16% after 6 months
to 1 year of treatment. A trial in 84 children with
a mean  age of 10 years gave similar results to
those in adults [5]. Longterm effects are not yet
defined. Few cases of leukaemia have been
reported. Adverse effects on growth and
development have not been reported [5]. The
safety of hydroxyurea therapy in pregnancy is
unclear [9]. Contraception should be practiced
by both women and men receiving hydroxyurea
and the uncertain outcome of an unplanned
pregnancy discussed frankly [5].
6) Bone marrow transplantation
Bone marrow transplantation is the only
currently available treatment that can cure SCA.
Unfortunately, it is associated with significant
mortality, morbidity and failure rates [6]. It was
first used in Europe for patients from Africa on
the assumption that the risks of disease in their
countries outweighed the hazards of
transplantation [1]. Children and adolescents
younger than 16 years of age who have severe
complications (stroke, recurrent acute chest
syndrome or refractory pain) and an HLA-
matched donor available, are the best candidates
for transplantation [1,12]. In a group of 22
children with sickle cell disease who received
marrow from HLA matched siblings, 15 (68%)
were cured and have remained symptom-free of
SCA, 4 (18%) rejected the marrow allograft and
SCA recurred, 1 had mixed chimerism with 30%
circulating sickle cells and 2 died after
transplantation [11]. The patients cured are likely
to be infertile and have an undefined risk of
chemotherapy-induced malignant condition or
other late complications of transplantation [13].
To the small group of patients who survived but
were not cured by transplantation, will add the
long-term effects of bisulfan and
cyclophosphamide to their medical problems,
including the possibility that the vascular insult
of the conditioning regimen used for
transplantation may ultimately exacerbate the
underlying SCA[12]. Almost all transplantation
cases to date
have utilized bone marrow from HLA-identical
siblings. Studies to use unrelated and HLA-
mismatched related donor transplantation to
expand transplantation for SCA is limited and
are still at the preliminary trial phases.
7) Umbilical cord blood transplantation [14]
Umbilical cord blood (UCB) is another
source of hematopoietic stem cells undergoing
investigation to support transplantation for SCA.
UCB has unique properties that makes it
potentially useful in this setting.
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Studies of CD34+ cells isolated from UCB show
enhanced generation of committed
hematopocetic progenitor cells, compared to
same cells from the bone marrows. UCB is also
immunologically naïve compared to adult
peripheral blood. Preliminary results indicate
that outcomes after UCB
transplantation from sibling donors for
hemoglobinopathies are similar to those after
bone marrow transplantation, but with an
additional advantage of a lower rate of graft
rejection.
Based on these observations there is a growing
interest in facilitating UCB collection and
storage from families who currently have a
child with sickle cell anemia or hematological
disorder and who are expecting another child.
8) Gene therapy
Despite 20 years of research, progress
towards implementing gene therapy for sickle
cell anemia has been slow and is still at the
experimental phase [14].
 There has been recent success in developing
two transgenic sickle cell mouse lines that
express exclusively human hemoglobin and
manifest the clinical features of SCA [6].
The principle of gene therapy is based
on the fact that a gene can be efficiently inserted
into repopulating hematopoietic cells to achieve
regulated expression in specific hematopoietic
lineages [14].
Relatively low efficiencies of gene
transfer with conventional, murine
oncoretroviral vectors coupled with the
requirement for a very high level of globin gene
expression in differentiating erythroblasts, have
been major barriers to rapid progress. Recent
studies have demonstrated that sickling
phenotype can be corrected by retroviral vector
mediated gene transfer, into repopulating stem
cells in murine models of sickle cell anemia.
Another breakthrough has been the adoption
of lentiviral vectors based on human
immunodeficiency virus for globin transfer
[14]. Great consideration is
being given to biosafety related to lentiviral
vector production,and strategies to ensure
absence of replication of competent retrovirus
are mandatory. The risk of mobilization of the
vector genome  in the context of subsequent
HIV infection still remains to be assessed [14].
Early clinical protocols to evaluate gene
therapy in patients with SCA are still in Phase I
studies, and are designed to evaluate toxicity.
Patients likely to participate are severely
affected adults with severe disease and low
endogenous levels of fetal hemoglobin[14].
Despite major advances in our
understanding of the molecular pathology,
pathophysiology, and control  and management
of inherited hemoglobin disorders, thousands
of infants and children with these diseases are
dying through lack of appropriate medical care.
It takes time to establish expertise in developing
countries for the control  and management of
these conditions, and the lessons learnt from
developed countries will need to be transmitted
to those countries in which they occur at a high
frequency[4].
IV- CONCLUSION
This review demonstrates that
remarkable progress has been made in recent
years to understand the pathophysiology and
development of new therapeutic approaches in
sickle cell anemia. Although most of this work
is still experimental, the future is promising. It
is hoped that this research will be translated
practically into a form that can be applied in
the less developed and poorer countries
especially in Africa where up to a third of the
population carry the hemoglobin  S gene.
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